<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article63</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/DAPA-CKD" style="display:block; margin-bottom:10px;">DAPA-CKD Original</a></li>
<h2><strong>DAPA-CKD</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Dapagliflozin in Patients with Chronic Kidney Disease". The New England Journal of Medicine. 2020.<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In patients with chronic kidney disease, with or without type 2 diabetes, does dapagliflozin improve renal outcomes and reduce cardiovascular mortality?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In patients with chronic kidney disease, dapagliflozin significantly reduced the risk of worsening kidney function, end-stage kidney disease, or death from renal or cardiovascular causes, regardless of diabetes status.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/><br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Multicenter, double-blind, randomized, placebo-controlled trial<br/>
N=4,304 patients with chronic kidney disease<br/>
Intervention: Dapagliflozin (10 mg once daily) (n=2,152)<br/>
Comparison: Placebo (n=2,152)<br/>
Median follow-up: 2.4 years<br/>
Primary outcome: Composite of â‰¥50% sustained eGFR decline, end-stage kidney disease, or death from renal or cardiovascular causes<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Adults with or without type 2 diabetes, eGFR of 25 to 75 ml/min/1.73m2, and urine albumin-to-creatinine ratio of 200 to 5,000 <br/>
Exclusion Criteria: Type 1 diabetes, polycystic kidney disease, certain glomerulonephritides, recent immunotherapy for primary or secondary kidney disease<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
Participants were randomized to receive dapagliflozin (10 mg once daily) or placebo. <br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcome: The primary composite outcome occurred in 9.2% of the dapagliflozin group and 14.5% of the placebo group (hazard ratio, 0.61; 95% CI, 0.51 to 0.72; P&lt;0.001; number needed to treat, 19).<br/>
Secondary Outcomes: Reduction in risk was observed for a composite of heart failure hospitalizations or cardiovascular death (hazard ratio, 0.71; P=0.009), and all-cause mortality was significantly lower in the dapagliflozin group (hazard ratio, 0.69; P=0.004).<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
The trial was stopped early due to efficacy, potentially reducing the statistical power for some secondary outcomes. Also, reversibility of the initial decline in eGFR after stopping dapagliflozin was not assessed post-trial.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Trial was funded by AstraZeneca.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
Detailed trial information and data sharing statement available at NEJM.org.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
